Deciding Kleene algebra terms equivalence in Coq

This paper presents a mechanically verified implementation of an algorithm for deciding the equivalence of Kleene algebra terms within the Coq proof assistant. The algorithm decides equivalence of two given regular expressions through an iterated process of testing the equivalence of their partial derivatives and does not require the construction of the corresponding automata. Recent theoretical and experimental research provides evidence that this method is, on average, more efficient than the classical methods based on automata. We present some performance tests, comparisons with similar approaches, and also introduce a generalization of the algorithm to decide the equivalence of terms of Kleene algebra with tests. The motivation for the work presented in this paper is that of using the libraries developed as trusted frameworks for carrying out certified program verification

Delegated RingCT: faster anonymous transactions

We present a modification to RingCT protocol with stealth addresses that makes it compatible with Delegated Proof of Stake based consensus mechanisms called Delegated RingCT. Our scheme has two building blocks: a customised version of an Integrated Signature and Encryption scheme composed of a public key encryption scheme and two signature schemes (a digital signature and a linkable ring signature); and non-interactive zero knowledge proofs. We give a description of the scheme, security proofs and a prototype implementation whose benchmarking is discussed. Although Delegated RingCT does not have the same degree of anonymity as other RingCT constructions, we argue that the benefits that the compatibility with DPoS consensus mechanisms brings constitute a reasonable trade-off for being able to develop an anonymous decentralised cryptocurrency faster and more scalable than existing ones

Acquisition of digital evidence in android smartphones

From an expert\u27s perspective, an Android phone is a large data repository that can be stored either locally or remotely. Besides, its platform allows analysts to acquire device data, collecting information about its owner and facts that are under investigation. This way, by exploring and cross referencing that rich data source, one can get information related to unlawful acts and its perpetrator. There are widespread and well documented approaches to forensic examining mobile devices and computers. Nevertheless, they are not specific nor detailed enough to examine modern smartphones, since these devices have internal memories whose removal or mirroring procedures are considered invasive and complex, due to difficulties in having direct hardware access. Furthermore, specific features of each smartphone platform have to be considered prior to acquiring its data. In order to deal with those challenges, this paper proposes a method to perform data acquisition of Android smartphones, regardless of version and manufacturer. The proposed approach takes into account existing techniques of computer and cell phone forensic examination, adapting them to specific Android characteristics, its data storage structure, popular applications and the conditions under which the device was sent to the forensic examiner. The method was defined in a broad fashion, not naming specific tools or techniques. Then, it was deployed into the examination of six Android smartphones, addressing different scenarios that an analyst might face, and was validated to perform an entire evidence acquisition

Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial.

There is no specific antiviral therapy recommended for coronavirus disease 2019 (COVID-19). In vitro studies indicate that the antiviral effect of chloroquine diphosphate (CQ) requires a high concentration of the drug.To evaluate the safety and efficacy of 2 CQ dosages in patients with severe COVID-19. This parallel, double-masked, randomized, phase IIb clinical trial with 81 adult patients who were hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection was conducted from March 23 to April 5, 2020, at a tertiary care facility in Manaus, Brazilian Amazon. - Patients were allocated to receive high-dosage CQ (ie, 600 mg CQ twice daily for 10 days) or low-dosage CQ (ie, 450 mg twice daily on day 1 and once daily for 4 days). - Label: Main Outcomes and Measures Primary outcome was reduction in lethality by at least 50% in the high-dosage group compared with the low-dosage group. Data presented here refer primarily to safety and lethality outcomes during treatment on day 13. Secondary end points included participant clinical status, laboratory examinations, and electrocardiogram results. Outcomes will be presented to day 28. Viral respiratory secretion RNA detection was performed on days 0 and 4. Out of a predefined sample size of 440 patients, 81 were enrolled (41 [50.6%] to high-dosage group and 40 [49.4%] to low-dosage group). Enrolled patients had a mean (SD) age of 51.1 (13.9) years, and most (60 [75.3%]) were men. Older age (mean [SD] age, 54.7 [13.7] years vs 47.4 [13.3] years) and more heart disease (5 of 28 [17.9%] vs 0) were seen in the high-dose group. Viral RNA was detected in 31 of 40 (77.5%) and 31 of 41 (75.6%) patients in the low-dosage and high-dosage groups, respectively. Lethality until day 13 was 39.0% in the high-dosage group (16 of 41) and 15.0% in the low-dosage group (6 of 40). The high-dosage group presented more instance of QTc interval greater than 500 milliseconds (7 of 37 [18.9%]) compared with the low-dosage group (4 of 36 [11.1%]). Respiratory secretion at day 4 was negative in only 6 of 27 patients (22.2%). - Label: Conclusions and Relevance The preliminary findings of this study suggest that the higher CQ dosage should not be recommended for critically ill patients with COVID-19 because of its potential safety hazards, especially when taken concurrently with azithromycin and oseltamivir. These findings cannot be extrapolated to patients with nonsevere COVID-19

Secure Biometric authentication way: a hybrid match-on-card system

International audienceThis article describes a complete original biometric system named Tactim based on the skin reaction coupled with security concepts. Even if the experiments showed that there is much work left, our approach has many advantages. Security and biometry are strongly linked together; the biometric features are original and strongly depend on the user's will. The proposed architecture claims to be a hybrid match on card system. The authentication step of a java card is lead by a specific applet which deduces the PIN from the biometric externally computes characteristics

Identification of human chromosome 22 transcribed sequences with ORF expressed sequence tags

Transcribed sequences in the human genome can be identified with confidence only by alignment with sequences derived from cDNAs synthesized from naturally occurring mRNAs. We constructed a set of 250,000 cDNAs that represent partial expressed gene sequences and that are biased toward the central coding regions of the resulting transcripts. They are termed ORF expressed sequence tags (ORESTES). The 250,000 ORESTES were assembled into 81,429 contigs. Of these, 1,181 (1.45%) were found to match sequences in chromosome 22 with at least one ORESTES contig for 162 (65.6%) of the 247 known genes, for 67 (44.6%) of the 150 related genes, and for 45 of the 148 (30.4%) EST-predicted genes on this chromosome. Using a set of stringent criteria to validate our sequences, we identified a further 219 previously unannotated transcribed sequences on chromosome 22. Of these, 171 were in fact also defined by EST or full length cDNA sequences available in GenBank but not utilized in the initial annotation of the first human chromosome sequence. Thus despite representing less than 15% of all expressed human sequences in the public databases at the time of the present analysis, ORESTES sequences defined 48 transcribed sequences on chromosome 22 not defined by other sequences. All of the transcribed sequences defined by ORESTES coincided with DNA regions predicted as encoding exons by genscan. (http://genes.mit.edu/GENSCAN.html)

The contribution of 700,000 ORF sequence tags to the definition of the human transcriptome

Open reading frame expressed sequences tags (ORESTES) differ from conventional ESTs by providing sequence data from the central protein coding portion of transcripts. We generated a total of 696,745 ORESTES sequences from 24 human tissues and used a subset of the data that correspond to a set of 15,095 full-length mRNAs as a means of assessing the efficiency of the strategy and its potential contribution to the definition of the human transcriptome. We estimate that ORESTES sampled over 80% of all highly and moderately expressed, and between 40% and 50% of rarely expressed, human genes. In our most thoroughly sequenced tissue, the breast, the 130,000 ORESTES generated are derived from transcripts from an estimated 70% of all genes expressed in that tissue, with an equally efficient representation of both highly and poorly expressed genes. In this respect, we find that the capacity of the ORESTES strategy both for gene discovery and shotgun transcript sequence generation significantly exceeds that of conventional ESTs. The distribution of ORESTES is such that many human transcripts are now represented by a scaffold of partial sequences distributed along the length of each gene product. The experimental joining of the scaffold components, by reverse transcription–PCR, represents a direct route to transcript finishing that may represent a useful alternative to full-length cDNA cloning

Identification of human chromosome 22 transcribed sequences with ORF expressed sequence tags

Transcribed sequences in the human genome can be identified with confidence only by alignment with sequences derived from cDNAs synthesized from naturally occurring mRNAs. We constructed a set of 250,000 cDNAs that represent partial expressed gene sequences and that are biased toward the central coding regions of the resulting transcripts. They are termed ORF expressed sequence tags (ORESTES). The 250,000 ORESTEs were assembled into 81,429 contigs. Of these, 1,181 (1.45%) were found to match sequences in chromosome 22 with at least one ORESTES contig for 162 (65.6%) of the 247 known genes, for 67 (44.6%) of the 150 related genes, and for 45 of the 148 (30.4%) EST-predicted genes on this chromosome. Using a set of stringent criteria to validate our sequences, we identified a further 219 previously unannotated transcribed sequences on chromosome 22. Of these, 171 were in fact also defined by EST or full length cDNA sequences available in GenBank but not utilized in the initial annotation of the first human chromosome sequence. Thus despite representing less than 15% of all expressed human sequences in the public databases at the time of the present analysis, ORESTEs sequences defined 48 transcribed sequences on chromosome 22 not defined by other sequences. All of the transcribed sequences defined by ORESTEs coincided with DNA regions predicted as encoding exons by GENSCAN.9723126901269